Introduction
============

In 2012, gastric cancer caused more than 723,100 deaths, remaining as the third leading cause of cancer deaths worldwide [@B1]. Owing to the increased use of endoscopies, standard D2 lymphadenectomy [@B2] and adjuvant chemotherapy [@B3], [@B4], the overall survival of resectable gastric cancer is increasing. Unfortunately, the overall survival of gastric cancer patients in China has remained dismal due to the advanced stage of the patients at the time of their first visit.

In spite of the development of chemotherapy, the survival time of metastatic gastric cancer patients has remained unsatisfactory, with a median survival time of approximate 12 months [@B5]-[@B8]. Both tumor-related and host-related factors can predict the prognosis of cancer patients [@B9]. Advanced gastric cancer patients are often accompanied with large tumor burdens and suffer from oral intake deficiency, outlet obstruction, tumor bleeding and ascites, which debilitates the nutrition of the patients [@B10]. The malnutrition, in return, accelerates the development of the tumor by suppressing the immunity of the patients [@B11]. Previous studies have reported that various nutritional indexes are associated with the prognosis of gastric cancer [@B10], [@B12]-[@B14]. Among them, nutritional risk screening 2002 (NRS 2002) is an easily applied and reproducible tool to predict the nutritional risk for in hospital patients [@B15]. After the first introduction in 2002, NRS 2002 was widely used to identify the risk for surgical complications [@B16]-[@B20] and survival outcome [@B21]. The European Society for Clinical Nutrition and Metabolism (ESPEN) also recommends the application of NRS 2002 for cancer patients [@B22] and surgery patients [@B23]. However, the prognostic value of NRS 2002 in metastatic gastric cancer remains unknown.

Therefore, our study aimed to explore the prognostic value of NRS 2002 in metastatic gastric cancer patients, including the patients who received palliative surgery.

Methods and patients
====================

Patients
--------

This study was approved by the institutional review board of Sun Yat-sen University Cancer Center. A total of 1719 patients diagnosed with metastatic gastric cancer at our institution between January 2000 and December 2015 were enrolled in this study. Patients were included if they had pathologically confirmed gastric adenocarcinoma with distant metastatic lesions, such as peritoneal dissemination, liver metastasis, lung metastasis, para-aortic lymph node (PAN) metastasis, and/or other distant metastases. Patients were excluded if the NRS 2002 score of the patient could not be assessed. Finally, 1664 patients were included in the present study (Fig [1](#F1){ref-type="fig"}). The following patient characteristics were collected: gender, age, Eastern Cooperative Oncology Group (ECOG) performance status (PS), tumor location, tumor size, histological type, NRS 2002 score, serum carcinoembryonic antigen (CEA), serum carbohydrate antigen 19-9 (CA19-9), serum albumin, palliative surgery, first-line chemotherapy, complications of palliative surgery and survival outcome. In this study, palliative surgery included palliative gastrectomy, bypass surgery and laparotomy/laparoscopic exploration. Postoperative morbidity was defined as higher than grade II complications according to the Clavien-Dindo classification [@B24], [@B25]. Postoperative mortality was defined as deaths that occurred either in hospital or within one month after palliative surgery.

Nutritional risk screening 2002
-------------------------------

NRS 2002 was first introduced by Kondrup et al. [@B15] and is evaluated by three components: impaired nutritional status (0-3 points), severity of disease (0-3 points) and age (0-1 points). The total NRS 2002 score ranges from 0 to 7 (Table [S1](#SM0){ref-type="supplementary-material"}). Previously, patients with NRS 2002 \< 3 and ≥ 3 (original scale) were classified as "no nutritional risk" and "nutritional risk," respectively. In the present study, the NRS 2002 score of the included patients was assessed by two trained dietitians who reviewed the electronic medical records retrospectively.

Statistical analysis
--------------------

Categorical variables are presented as numbers with percentages and compared using the χ^2^ test or Fisher\'s exact test. Overall survival (OS) was calculated from the date of initial diagnosis to death from any cause or date of last follow-up. Progression-free survival (PFS) was measured from the date of initial diagnosis to the date of progression or death. The survival difference was compared by Kaplan-Meier curves using log-rank test. Receiver operating characteristic (ROC) curves were used to verify the efficacy of NRS 2002 to predict the 2-year OS, and the risk of postoperative complications of palliative surgery. The performance of the ROC curves was evaluated using the areas under the curve (AUC). The cut-off value for NRS 2002 was determined by the highest Youden index in the ROC curves. Then, the NRS 2002 was regrouped by the new cut-off value (regrouping scale). Variables with P \< 0.05 in the univariable analysis were entered into the multivariate Cox regression. All tests were two-tailed, and P \< 0.05 was considered significant. All statistical analyses were performed using SPSS software version 23.0 (IBM Inc., Armonk, NY, USA).

Results
=======

A total of 1664 subjects were included in the present study, with a median age of 56 (46-64) years; 1052 (63.2%) patients were male, and 800 (48.1%) patients received palliative surgery. The median BMI was 20.6 (18.6-22.9) kg/m^2^. In this sample, 254 (15.3%) patients had lost more than 15% of their bodyweight in 3 months. The NRS 2002 score varied from 1 to 5, and the number of patients with an NRS 2002 score at 1, 2, 3, 4 and 5 points were 350 (21.0%), 234 (14.1%), 336 (20.2%), 647 (38.9%) and 97 (5.8%), respectively (Fig [1](#F1){ref-type="fig"}).

ROC curves predicting 2-year OS and the risk of complication
------------------------------------------------------------

The AUCs of ROC curves predicting 2-year OS and the risk of complication are summarized in Table [1](#T1){ref-type="table"}. Regarding the ROC curve predicting 2-year OS, the AUC was 0.578 (95% CI: 0.534-0.621, P \< 0.001) for NRS 2002 score, and the optimal cut-off value was 3.5 with sensitivity at 46.2% and specificity at 66.3% (Fig [2](#F2){ref-type="fig"}a). Regarding the ROC curve for the risk of complication, the AUC was 0.567 (95% CI: 0.501-0.632, P = 0.042) for NRS 2002 score, and the optimal cut-off value was 3.5 with sensitivity at 60.9% and specificity at 51.6% (Fig [2](#F2){ref-type="fig"}b). Therefore, we regrouped patients into groups with NRS 2002 score ≤ and \> 3 (regrouping scale). ROC curves (Fig [2](#F2){ref-type="fig"}c-f, Table [1](#T1){ref-type="table"}) showed that, compared with the original scale (NRS 2002 \< and ≥ 3), the regrouping scale provided similar risk stratification predicting 2-year OS (AUC: 0.563 vs. 0.564, P \> 0.05) but better stratification for the prediction of the risk of complication of palliative surgery (AUC: 0.563 vs. 0.522, P = 0.050).

Characteristic of patients according to the regrouping scale
------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, the number of patients with NRS 2002 ≤ and \> 3 were 920 and 744, respectively. Patients with NRS 2002 \> 3 tended to have worse PS (P \< 0.001), larger tumor size (P \< 0.001), lower serum albumin (P = 0.010), more palliative surgery (P \< 0.001), and less first-line chemotherapy (P \< 0.001). For the 800 patients that received palliative surgery, patients with NRS 2002 \> 3 had higher postoperative morbidity (13.3% vs. 8.5%, P = 0.027) and mortality (5.3% vs. 2.0%, P = 0.013) than those with NRS 2002 ≤ 3.

Survival
--------

The median OS for patients with NRS 2002 ≤ and \> 3 were 12.63 (95% CI: 11.63-13.64) months and 9.03 (95% CI: 8.26-9.81) months, respectively (Fig [3](#F3){ref-type="fig"}a), and the OS difference was significant (P \< 0.001). Patients with NRS 2002 \> 3 had a shorter PFS than those with NRS 2002 ≤ 3 (median PFS: 6.70 \[95% CI: 6.25-7.15\] vs. 7.70 \[95% CI: 7.11-8.29\], P = 0.002) (Fig [3](#F3){ref-type="fig"}b).

For patients receiving palliative surgery, patients with NRS 2002 \> 3 had a shorter OS (median OS: 11.77 \[95% CI: 10.12-13.42\] vs. 17.30 \[95% CI: 14.42-20.18\], P \< 0.001) (Fig [3](#F3){ref-type="fig"}c) and PFS (median PFS: 8.37 \[95% CI: 7.51-9.22\] vs. 10.23 \[95% CI: 8.75-9.91\], P \< 0.001) (Fig [3](#F3){ref-type="fig"}d) than those with NRS 2002 ≤ 3.

For patients who did not receive palliative surgery, patients with NRS 2002 \> 3 had a shorter OS (median OS: 6.93 \[95% CI: 6.17-7.70\] vs. 9.73 \[95% CI: 8.66-10.81\], P \< 0.001) (Fig [3](#F3){ref-type="fig"}e) and PFS (median PFS: 4.83 \[95% CI: 4.01-5.66\] vs. 5.63 \[95% CI: 5.14-6.12\], P = 0.011) (Fig [3](#F3){ref-type="fig"}f) than those with NRS 2002 ≤ 3.

In the multivariable analysis of OS, PS (P = 0.001), tumor size (P = 0.001), histological type (P = 0.001), serum CEA (P = 0.007), CA19-9 (P \< 0.001), palliative surgery (P \< 0.001), first-line chemotherapy (P \< 0.001) and regrouping NRS 2002 scale (P \< 0.001) were the independent prognostic factors (Table [3](#T3){ref-type="table"}). In the multivariable analysis of PFS, the regrouping NRS 2002 scale (P = 0.028) remained the independent prognostication (Table [4](#T4){ref-type="table"}).

Discussion
==========

Based on the analysis of 128 randomized clinical studies, Kondrup et al. [@B15] introduced a useful screening tool, NRS 2002, to identify patients who are likely to benefit from nutritional support. Several studies also reported an association between NRS 2002 and clinical outcomes in cancer patients [@B18], [@B26], [@B27], including gastric cancer patients [@B16], [@B21]. In the present study, our results demonstrated that NRS 2002 was an independent factor that predicted the PFS and OS for metastatic gastric cancer. Moreover, for patients who received palliative surgery, the regrouping NRS 2002 scale (NRS 2002 ≤ and \> 3) could effectively predict postoperative morbidity and mortality.

Gastric cancer patients often have a higher prevalence of nutritional risk than other disease. Previous studies showed that 32.4-50.7% of gastric cancer patients had an NRS 2002 score ≥ 3 [@B16], [@B20], [@B21], [@B28], which indicated a high nutritional risk for gastric cancer patients. In the present study, our results demonstrated that the percentage of metastatic gastric cancer patients with NRS 2002 score ≥ 3 was 64.9%, which is higher than that of previous studies. In addition, for patients who were supposed to receive palliative surgery, the percentage of patients with NRS 2002 ≥ 3 was 68.6%. This difference was mainly due to the older age, greater disease severity and more comorbidity for metastatic gastric cancer patients. For example, metastatic gastric cancer patients often suffered from outlet obstruction or massive ascites, which would lead to a higher NRS 2002 score.

Malnutrition had been reported as an independent factor associated with postoperative complications [@B16], [@B20], [@B29] and survival outcomes [@B21], [@B30]. Serum albumin was a useful biomedical factor to identify the nutritional status of the patients. Lien et al. [@B31] reported that gastric cancer patients with lower preoperative serum albumin levels were associated with worse survival. Our data revealed that metastatic gastric cancer patients with NRS 2002 \> 3 were highly correlated with hypoalbuminemia, larger tumor size and worse performance status. Moreover, our results showed that patients with NRS 2002 \> 3 had shorter OS and PFS than those patients with NRS 2002 ≤ 3, which indicated that NRS 2002 scale was not only a simple tool to distinguish the nutritional status and tumor burden of the patients but also a practical tool to predict the survival outcome for metastatic gastric cancer patients.

Although palliative gastrectomy did not show the survival benefit for metastatic gastric cancer [@B32], palliative surgery could relieve the cancer-related symptoms, such as tumor bleeding, outlet obstruction and perforation. Our data revealed that the regrouping NRS 2002 scale (NRS 2002 ≤ and \> 3) could predict the risk of complications and postoperative mortality for metastatic gastric cancer patients. Therefore, metastatic gastric cancer patients with NRS 2002 \> 3 should receive interventions with nutritional supplement to correct immunonutritional disorders. Qiu et al. reported that advanced gastric cancer patients could benefit from nutrition improvement after nutrition support [@B21]. However, only 30.3% of advanced gastric cancer patients had nutrition improvement after nutrition support. Therefore, whether malnutrition is a cause or a consequence of tumor progression remains unclear. Moreover, for patients who receive palliative surgery, whether the preoperative nutrition support could reduce the risk of postoperative morbidity and mortality is still uncertain.

There were several limitations in our study. First, this was a substantial retrospective study from a single center. Second, the study time span was 15 years. Third, because the external validation by an independent cohort was not available in the present study, the results of our study should be interpreted cautiously. Therefore, in the future, large-scale and well-designed prospective trials are needed to verify the results.

Conclusions
===========

In conclusion, the present study indicated that the NRS 2002 scale (regrouping scale) was an independent prognostic factor to predict the morbidity, mortality and survival outcomes for metastatic gastric cancer.
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![Flowchart of patient enrollment.](jcav10p0112g001){#F1}

![Receiver operating characteristic (ROC) curves predicting 2-year overall survival (OS) and risk of complication. a. Nutritional risk screening (NRS) 2002 score predicting 2-year OS (P\< 0.001); b. Nutritional risk screening (NRS) 2002 score predicting the risk of complication (P = 0.042); c. NRS 2002 \< and ≥ 3 (original scale) predicting 2-year OS (P= 0.003); d. NRS 2002 \< 3 and ≥ 3 (original scale) predicting the risk of complication (P= 0.503). e. NRS 2002 ≤ 3 and \> 3 (regrouped scale) predicting 2-year OS (P= 0.004); f. NRS 2002 ≤ 3 and \> 3 (regrouped scale) predicting the risk of complication (P= 0.050).](jcav10p0112g002){#F2}

![Kaplan-Meier estimates of overall survival and progression-free survival in (a, b) all patients, (c, d) patients who received palliative surgery and (e, f) patients who did not receive palliative surgery between NRS 2002 ≤ 3 and \> 3 groups. a P \< 0.001, b P = 0.002, c P \< 0.001, d P \< 0.001, e P\< 0.001, f P = 0.011.](jcav10p0112g003){#F3}

###### 

Summary of the ROC curves predicting 2-year OS and the risk of complication

  Group                 2-year OS                        Risk of complication                         
  --------------------- --------------------- ---------- ---------------------- --------------------- -------
  NRS 2002              0.578 (0.534-0.621)   \< 0.001                          0.567 (0.501-0.632)   0.042
  NRS 2002 \< and ≥ 3   0.564 (0.521-0.608)   0.003                             0.522 (0.459-0.585)   0.503
  NRS 2002 ≤ and \> 3   0.563 (0.521-0.64)    0.004                             0.563 (0.500-0.626)   0.050

ROC receiver operating characteristic; OS overall survival; AUC area under the curve; NRS 2002 nutritional risk screening 2002.

###### 

Clinicopathological characteristics of 1664 metastatic gastric cancer patients according to the regrouping NRS 2002 scale

  Characteristics               NRS 2002 ≤ 3   NRS 2002 \> 3   P-value
  ----------------------------- -------------- --------------- ----------
  **No. of patients**           920            744             
  **Sex, n**                                                   0.583
  Male                          587 (63.8)     465(62.5)       
  Female                        333 (36.2)     279 (37.5)      
  **Age**                                                      \< 0.001
  \< 70 years                   848 (92.4)     602 (81.0)      
  ≥ 70 years                    70 (7.6)       141 (19.0)      
  **Performance status, n**                                    \< 0.001
  \< 2                          833 (90.5)     602 (81.0)      
  ≥ 2                           87 (9.5)       141 (19.0)      
  **Tumor location**                                           0.092
  Entire stomach                40 (4.4)       46 (6.2)        
  Non-entire stomach            879 (95.6)     697 (93.8)      
  **Size**                                                     \< 0.001
  \< 5 cm                       346 (42.5)     201 (30.6)      
  5-10 cm                       382 (46.9)     352 (53.6)      
  \> 10 cm                      87 (10.7)      104 (15.8)      
  **Histological type**                                        0.326
  Well differentiated           131 (14.7)     92 (13.0)       
  Poorly differentiated         761 (85.3)     617 (87.0)      
  **CEA (ng/ml)**                                              0.885
  \< 5                          496 (58.8)     402 (59.2)      
  ≥ 5                           347 (41.2)     277 (40.8)      
  **CA19-9 (U/ml)**                                            0.525
  \< 35                         476 (59.5)     376 (57.8)      
  ≥ 35                          324 (40.5)     274 (42.2)      
  **Serum albumin**                                            0.010
  \< 3.0 g/dl                   20 (2.3)       33 (4.6)        
  ≥ 3.0 g/dl                    850 (97.7)     95.4 (95.4)     
  **Palliative surgery^\*^**                                   \< 0.001
  Yes                           402 (43.7)     398 (53.5)      
  No                            518 (56.3)     346 (46.5)      
  **First-line chemotherapy**                                  \< 0.001
  Yes                           700 (76.2)     465 (62.7)      
  No                            23.8 (23.8)    277 (37.3)      
  **Morbidity**                                                0.027
  Yes                           34 (8.5)       53 (13.3)       
  No                            368 (91.5)     345 (86.7)      
  **Mortality**                                                0.013
  Yes                           8 (2.0)        21 (5.3)        
  No                            394 (98.0)     377 (94.7)      

NRS 2002 nutritional risk screening 2002; CEA baseline carcinoembryonic antigen; CA19-9 baseline carbohydrate antigen 19-9; ^\*^ Palliative surgery included palliative gastrectomy, bypass surgery and laparotomy/laparoscopic exploration.

###### 

Univariable analysis and multivariable analysis of overall survival for 1664 metastatic gastric cancer patients

  Variables                     Univariate analysis   Multivariate analysis                      
  ----------------------------- --------------------- ----------------------- ------------------ ----------
  **Sex**                                             0.098                                      
  Male                          1                                                                
  Female                        0.90 (0.80-1.02)                                                 
  **Age**                                             0.034                                      
  \< 70 years                   1                                                                
  ≥ 70 years                    1.20 (1.01-1.42)                                                 
  **Performance status, n**     \< 0.001                                      \< 0.001           
  \< 2                          1                                             1                  
  ≥ 2                           1.48 (1.26-1.73)                              1.39 (1.16-1.67)   
  **Tumor location**                                  0.101                                      
  Entire stomach                1                                                                
  Non-entire stomach            0.80 (0.61-1.04)                                                 
  **Size**                                            \< 0.001                                   0.001
  \< 5 cm                       1                                             1                  
  5-10 cm                       1.32 (1.15-1.50)      \< 0.001                1.28 (1.10-1.49)   0.001
  \> 10 cm                      1.71 (1.41-2.08)      \< 0.001                1.41 (1.13-1.74)   0.002
  **Histological type**                               0.003                                      0.001
  Well differentiated           1                                             1                  
  Poorly differentiated         1.29 (1.09-1.53)                              1.40 (1.14-1.71)   
  **CEA (ng/ml)**                                     \< 0.001                                   0.007
  \< 5                          1                                             1                  
  ≥ 5                           1.39 (1.23-1.57)                              1.22 (1.06-1.41)   
  **CA19-9 (U/ml)**                                   \< 0.001                                   \< 0.001
  \< 35                         1                                             1                  
  ≥ 35                          1.38 (1.21-1.56)                              1.33 (1.16-1.41)   
  **Serum albumin**                                   0.004                                      
  \< 3.0 g/dl                   1.61 (1.16-2.22)                                                 
  ≥ 3.0 g/dl                    1                                                                
  **Palliative surgery^\*^**                          \< 0.001                                   \< 0.001
  No                            1                                             1                  
  Yes                           0.55 (0.49-0.62)                              0.48 (0.42-0.55)   
  **First-line chemotherapy**   \< 0.001                                      \< 0.001           
  Yes                           0.34 (0.30-0.38)                              0.30 (0.26-0.34)   
  No                            1                                             1                  
  **NRS 2002 scale**                                  \< 0.001                                   \< 0.001
  ≤ 3                           1                                             1                  
  \> 3                          1.34 (1.19-1.51)                              1.29 (1.12-1.48)   

NRS 2002 nutritional risk screening 2002; CEA baseline carcinoembryonic antigen; CA19-9 baseline carbohydrate antigen 19-9; ^\*^ Palliative surgery included palliative gastrectomy, bypass surgery and laparotomy/laparoscopic exploration.

###### 

Univariable analysis and multivariable analysis of progression-free survival for 1664 metastatic gastric cancer patients

  Variables                     Univariate analysis   Multivariate analysis                      
  ----------------------------- --------------------- ----------------------- ------------------ ----------
  **Sex**                                             0.027                                      
  Male                          1                                                                
  Female                        0.88 (0.79-0.99)                                                 
  **Age**                                             0.928                                      
  \< 70 years                   1                                                                
  ≥ 70 years                    1.01 (0.86-1.18)                                                 
  **Performance status, n**                           0.001                                      0.001
  \< 2                          1                                             1                  
  ≥ 2                           1.30 (1.12-1.51)                              1.33 (1.12-1.59)   
  **Tumor location**                                  0.024                                      
  Entire stomach                1                                                                
  Non-entire stomach            0.75 (0.69-0.96)                                                 
  **Size**                                            \< 0.001                                   
  \< 5 cm                       1                                             1                  0.013
  5-10 cm                       1.21 (1.07-1.37)      0.002                   1.18 (1.03-1.36)   
  \> 10 cm                      1.54 (1.28-1.85)      \< 0.001                1.30 (1.06-1.59)   
  **Histological type**                               \< 0.001                                   \< 0.001
  Well differentiated           1                                             1                  
  Poorly differentiated         1.36 (1.16-1.59)                              1.56 (1.30-1.89)   
  **CEA (ng/ml)**                                     \< 0.001                                   0.002
  \< 5                          1                                             1                  
  ≥ 5                           1.37 (1.22-1.53)                              1.23 (1.08-1.71)   
  **CA19-9 (U/ml)**                                   \< 0.001                                   \< 0.001
  \< 35                         1                                             1                  
  ≥ 35                          1.48 (1.32-1.66)                              1.50 (1.32-1.71)   
  **Serum albumin**                                   0.001                                      
  \< 3.0 g/dl                   1.66 (1.23-2.26)                                                 
  ≥ 3.0 g/dl                    1                                                                
  **Palliative surgery^\*^**                          \< 0.001                                   \< 0.001
  No                            1                                             1                  
  Yes                           0.50 (0.45-0.56)                              0.43 (0.38-0.49)   
  **First-line chemotherapy**   \< 0.001                                      \< 0.001           
  Yes                           0.52 (0.46-0.58)                              0.47 (0.41-0.54)   
  No                            1                                             1                  
  **NRS 2002 scale**                                  0.002                                      0.028
  ≤ 3                           1                                             1                  
  \> 3                          1.18 (1.06-1.31)                              1.16 (1.02-1.31)   

NRS 2002 nutritional risk screening 2002; CEA baseline carcinoembryonic antigen; CA19-9 baseline carbohydrate antigen 19-9; ^\*^ Palliative surgery included palliative gastrectomy, bypass surgery and laparotomy/laparoscopic exploration.
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